The role of SPINK1 in ETS rearrangement-negative prostate cancers

Scott A Tomlins1, Daniel R Rhodes, Jianjun Yu

  • 1Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Cancer Cell
|June 10, 2008
PubMed

Insights

Researchers identified SPINK1 outlier expression in ETS rearrangement-negative prostate cancers. This finding is a potential noninvasive biomarker for predicting recurrence after surgery.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • ETS gene fusions are common in prostate cancer, but molecular drivers in ETS-negative cases remain largely unknown.
  • Understanding these drivers is crucial for developing targeted therapies and improving patient outcomes.

Purpose of the Study:

  • To identify molecular alterations in ETS rearrangement-negative prostate cancers.
  • To investigate the role of SPINK1 expression as a potential biomarker and therapeutic target.

Main Methods:

  • Utilized outlier meta-analysis (meta-COPA) to detect SPINK1 outlier expression.
  • Validated mutual exclusivity between SPINK1 expression and ETS fusion status.
  • Assessed SPINK1 detectability in urine and its predictive value for biochemical recurrence.
  • Used the 22RV1 cell line to model SPINK1 outlier expression and test functional significance.

Main Results:

  • Identified SPINK1 outlier expression in approximately 10% of ETS rearrangement-negative prostate cancers.
  • Confirmed SPINK1 expression is mutually exclusive with ETS fusions.
  • Demonstrated noninvasive detection of SPINK1 outlier expression in urine.
  • Established SPINK1 outlier expression as an independent predictor of biochemical recurrence post-resection.
  • Showcased SPINK1 knockdown in 22RV1 cells attenuating invasion, suggesting a functional role.

Conclusions:

  • SPINK1 outlier expression represents a distinct molecular subtype of ETS rearrangement-negative prostate cancer.
  • SPINK1 serves as a potential noninvasive biomarker for predicting prostate cancer recurrence.
  • Targeting SPINK1 may offer a therapeutic strategy for a subset of aggressive prostate cancers.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.